Plasma Derived Therapy Market Analysis

Plasma Derived Therapy Market Analysis

To get key market trends

  Download Free Sample

Based on product, the global market is classified into immunoglobulins, coagulation factors, albumin, and other products. Immunoglobulin market held 48.1% business share in 2022.
 

• The segment is projected to witness significant growth owing to increasing use of immunoglobulins for the treatment of several complex diseases globally. Also, growing awareness about the advanced procedures among the population coupled with increasing adoption of immunoglobulin for treatment of several diseases is anticipated to boost the demand for immunoglobulin therapy.
   
• Further, the segment growth is attributed to increasing prevalence of Kawasaki disease (KD), immune thrombocytopenic purpura (ITP), primary immunodeficiency, and other neuromuscular diseases among population.
   

Based on application, the plasma derived therapy market is categorized into primary immunodeficiency diseases, haemophilia, idiopathic thrombocytopenic purpura (ITP) and others. Haemophilia segment dominated the global market share and was valued at USD 6.5 billion in 2022.
 

• Haemophilia is a rare bleeding disorder that restricts the normal blood clotting. The segment growth is attributed to increasing prevalence of haemophilia in developed and underdeveloped countries. According to the data published by World Federation of Haemophilia in 2020, around 209,614 people are living with haemophilia across 120 countries in the world. Adding to this, haemophilia A is most prevalent type of condition. Therefore, growing prevalence of haemophilia coupled with large patient pool will significantly influence the plasma derived therapy demand during the analysis period to reach over USD 13.3 billion by the year 2032.

North America market held over 52.2 % business share in 2022 and is projected to experience remarkable growth during the foreseeable future.
 

• Favourable government initiatives and expanding coverage of plasma collection centres by leading market players will offer growth opportunities to the market. Furthermore, increasing awareness about plasma derived therapies among blood donors, and favourable initiatives undertaken by major market players to stimulate blood donation in the region will accelerate the regional revenue trends.
   
• Adding to this, U.S. market dominated the North America plasma derived therapy industry in 2022 with significant demand as well as high plasma volume in the region. Increase in number of patients with rare diseases has strengthened the growth potential of market players operating in the country.